These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 17183065)
1. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Zhang B; Sun T; Xue L; Han X; Zhang B; Lu N; Shi Y; Tan W; Zhou Y; Zhao D; Zhang X; Guo Y; Lin D Carcinogenesis; 2007 May; 28(5):1067-73. PubMed ID: 17183065 [TBL] [Abstract][Full Text] [Related]
2. Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma. Cao Y; Miao XP; Huang MY; Deng L; Lin DX; Zeng YX; Shao JY Mol Carcinog; 2010 Nov; 49(11):944-50. PubMed ID: 20842669 [TBL] [Abstract][Full Text] [Related]
3. Functional variants in cell death pathway genes and risk of pancreatic cancer. Yang M; Sun T; Wang L; Yu D; Zhang X; Miao X; Liu J; Zhao D; Li H; Tan W; Lin D Clin Cancer Res; 2008 May; 14(10):3230-6. PubMed ID: 18483392 [TBL] [Abstract][Full Text] [Related]
4. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. Sun T; Zhou Y; Li H; Han X; Shi Y; Wang L; Miao X; Tan W; Zhao D; Zhang X; Guo Y; Lin D J Exp Med; 2005 Oct; 202(7):967-74. PubMed ID: 16186185 [TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma. Zhou RM; Wang N; Chen ZF; Duan YN; Sun DL; Li Y J Gastroenterol Hepatol; 2010 Mar; 25(3):555-61. PubMed ID: 20074157 [TBL] [Abstract][Full Text] [Related]
6. Polymorphisms of death pathway genes FAS and FASL and risk of premalignant gastric lesions. Hsu PI; Lu PJ; Wang EM; Ger LP; Lo GH; Tsay FW; Chen TA; Yang HB; Chen HC; Lin WS; Lai KH Anticancer Res; 2008; 28(1A):97-103. PubMed ID: 18383830 [TBL] [Abstract][Full Text] [Related]
7. Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer. Park JY; Lee WK; Jung DK; Choi JE; Park TI; Lee EB; Cho S; Park JY; Cha SI; Kim CH; Kam S; Jung TH; Jheon S Clin Cancer Res; 2009 Mar; 15(5):1794-800. PubMed ID: 19240174 [TBL] [Abstract][Full Text] [Related]
8. Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case-control analysis. Li C; Wu W; Liu J; Qian L; Li A; Yang K; Wei Q; Zhou J; Zhang Z Pharmacogenet Genomics; 2006 Apr; 16(4):245-51. PubMed ID: 16538171 [TBL] [Abstract][Full Text] [Related]
10. [Relationship between FAS/FASL gene polymorphisms and susceptibility of coal worker's pneumoconiosis]. Ni CH; Song ZF; Jia XM; Li AP; Li CP; Li SK; Li YM; Wang ZL; Zhou Y; Wang SY; Zhang ZD; Zhou JW Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2007 Sep; 25(9):532-6. PubMed ID: 17997887 [TBL] [Abstract][Full Text] [Related]
11. Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Li C; Larson D; Zhang Z; Liu Z; Strom SS; Gershenwald JE; Prieto VG; Lee JE; Ross MI; Mansfield PF; Cormier JN; Duvic M; Grimm EA; Wei Q Pharmacogenet Genomics; 2006 Apr; 16(4):253-63. PubMed ID: 16538172 [TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms of IL-1A, IL-1B, IL-1RN, NFKB1, FAS, and FASL, and risk of silicosis in a Chinese occupational population. Wu F; Xia Z; Qu Y; Tang Y; Cao D; Sun P; Christiani DC Am J Ind Med; 2008 Nov; 51(11):843-51. PubMed ID: 18666137 [TBL] [Abstract][Full Text] [Related]
13. A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer. Sung WW; Wang YC; Cheng YW; Lee MC; Yeh KT; Wang L; Wang J; Chen CY; Lee H Clin Cancer Res; 2011 Sep; 17(18):5991-9. PubMed ID: 21807637 [TBL] [Abstract][Full Text] [Related]
14. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Reichert TE; Strauss L; Wagner EM; Gooding W; Whiteside TL Clin Cancer Res; 2002 Oct; 8(10):3137-45. PubMed ID: 12374681 [TBL] [Abstract][Full Text] [Related]
16. FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies. Zhang Z; Xue H; Gong W; Wang M; Yuan L; Han S; Zhang Z Carcinogenesis; 2009 Mar; 30(3):487-93. PubMed ID: 19168581 [TBL] [Abstract][Full Text] [Related]
17. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174 [TBL] [Abstract][Full Text] [Related]
18. [Genetic polymorphisms of apoptosis-associated genes FAS and FASL and risk of colorectal cancer]. Yang S; Miao XP; Zhang XM; Sun T; Qu SN; Xiong P; Ye YJ; Guo YL; Tan W; Wang S; Lin DX Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2132-5. PubMed ID: 16313826 [TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in the apoptosis-associated genes FAS and FASL and risk of oral cancer and malignant potential of oral premalignant lesions in a Taiwanese population. Wang LH; Ting SC; Chen CH; Tsai CC; Lung O; Liu TC; Lee CW; Wang YY; Tsai CL; Lin YC J Oral Pathol Med; 2010 Feb; 39(2):155-61. PubMed ID: 20359312 [TBL] [Abstract][Full Text] [Related]
20. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. Zhang X; Miao X; Sun T; Tan W; Qu S; Xiong P; Zhou Y; Lin D J Med Genet; 2005 Jun; 42(6):479-84. PubMed ID: 15937082 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]